Pfizer predicts $54bn in 2022 revenue from Comirnaty and Paxlovid 08-Feb-2022 By Rachel Arthur Pfizer forecasts $32bn in revenue for COVID-19 vaccine Comirnaty, and $22bn for oral COVID-19 treatment Paxlovid, in 2022.